admin – Page 8066 – Get News Story

Ocular Hypertension Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, and others.

DelveInsight’s, “Ocular Hypertension Pipeline Insight 2023” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ocular Hypertension pipeline landscape. It covers the Ocular Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ocular Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ocular Hypertension Pipeline Report

DelveInsight’s Ocular Hypertension pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ocular Hypertension treatment.
The leading Ocular Hypertension Companies include Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others.
Promising Ocular Hypertension Pipeline Therapies include NCX-470, QLS-101, TO-O-1001, and others.
December 2023: AbbVie announced a study of Phase 1 & 2 clinical trials for AGN-193408 SR and Lumigan. This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension.
November 2023: Nicox Ophthalmics Inc. announced a study of Phase 3 clinical trials for NCX 470 0.1% and Latanoprost 0.005%. The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

Request a sample and discover the recent advances in Ocular Hypertension Treatment Drugs @ Ocular Hypertension Pipeline Report

The Ocular Hypertension pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ocular Hypertension drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ocular Hypertension clinical trial landscape.

Ocular Hypertension Overview

Ocular hypertension occurs when the pressure inside the eye exceeds the range considered normal and goes higher than 21 mm Hg. The increase in intraocular pressure (progressive with age, although may also be due to other disorders or causes) is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease.

Find out more about Ocular Hypertension Treatment Landscape @ Drugs for Ocular Hypertension Treatment

Ocular Hypertension Emerging Drugs Profile

NCX-470: Nicox
QLS-101: Qlaris Bio
TO-O-1001: TheratOcular Biotek Co., Ltd.

Ocular Hypertension Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Ocular Hypertension. The Ocular Hypertension companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

DelveInsight’s Ocular Hypertension pipeline report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Ocular Hypertension Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Learn more about the emerging Ocular Hypertension Pipeline Therapies @ Ocular Hypertension Clinical Trials Assessment

Scope of the Ocular Hypertension Pipeline Report

Coverage- Global
Ocular Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Ocular Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Ocular Hypertension Companies- Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others.
Ocular Hypertension Pipeline Therapies- NCX-470, QLS-101, TO-O-1001, and others.

Dive deep into rich insights for new drugs for Ocular Hypertension treatment, Visit @ Ocular Hypertension Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Ocular Hypertension: Overview
Pipeline Therapeutics
Therapeutic Assessment
Ocular Hypertension– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
NCX-470: Nicox
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
QLS-101: Qlaris Bio
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
TO-O-1001: TheratOcular Biotek Co., Ltd.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Ocular Hypertension Key Companies
Ocular Hypertension Key Products
Ocular Hypertension- Unmet Needs
Ocular Hypertension- Market Drivers and Barriers
Ocular Hypertension- Future Perspectives and Conclusion
Ocular Hypertension Analyst Views
Ocular Hypertension Key Companies
Appendix

For further information on the Ocular Hypertension Pipeline Therapeutics, reach out @ Ocular Hypertension Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ocular Hypertension Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, and others.

Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen

DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Osteoarthritis Pipeline Report

DelveInsight’s Osteoarthritis pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis treatment.
The leading companies working in the Osteoarthritis Market include Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
Promising Osteoarthritis Pipeline Therapies in the various stages of development include Hyaluronic Acid, V120083, Naproxen, EP-104IAR, Hyalgan, and others.
October 2023: Regeneron Pharmaceuticals announced a study of Phase 3 clinical trials for Fasinumab. The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
October 2023: Biosplice Therapeutics Inc. announced a study of Phase 3 clinical trials for Lorecivivint. This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize standard outcomes to evaluate the safety and efficacy of lorecivivint.

Request a sample and discover the recent advances in Osteoarthritis Treatment Drugs @ Osteoarthritis Pipeline Report

In the Osteoarthritis pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, Osteoarthritis clinical trials, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Osteoarthritis Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected.

Find out more about Osteoarthritis Therapeutics Assessment @ Osteoarthritis Preclinical and Discovery Stage Products

Osteoarthritis Emerging Drugs Profile

Lorecivivint: Biosplice Therapeutics
CYP 004: Cynata Therapeutics
JTA-004: Bone Therapeutics
SMUP-IA-01: Medipost
TTAX03: Tissue Tech

Osteoarthritis Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.

DelveInsight’s Osteoarthritis pipeline report covers around 130+ products under different phases of Osteoarthritis clinical trials development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous

Osteoarthritis Pipeline Products have been categorized under various Molecule types such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Learn more about the emerging Osteoarthritis Pipeline Therapies @ Osteoarthritis Clinical Trials Assessment

Scope of the Osteoarthritis Pipeline Report

Coverage- Global
Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
Osteoarthritis Pipeline Therapies- Hyaluronic Acid, V120083, Naproxen, EP-104IAR, Hyalgan, and others.

Dive deep into rich insights for new drugs for Osteoarthritis Treatment, Visit @ Osteoarthritis Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Osteoarthritis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Osteoarthritis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Lorecivivint: Biosplice Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TTAX03: Tissue Tech
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
GLPG-0555: Gilead Sciences
Drug profiles in the detailed report…..
Preclinical Stage Products
Protego-PD: Plakous Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Osteoarthritis Key Companies
Osteoarthritis Key Products
Osteoarthritis- Unmet Needs
Osteoarthritis- Market Drivers and Barriers
Osteoarthritis- Future Perspectives and Conclusion
Osteoarthritis Analyst Views
Osteoarthritis Key Companies
Appendix

For further information on the Osteoarthritis Pipeline therapeutics, reach out to Osteoarthritis Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen

Prostate Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics

DelveInsight’s, “Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Prostate Cancer Pipeline Report

DelveInsight’s Prostate Cancer pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Prostate Cancer treatment.
The leading companies working in the Prostate Cancer Market include Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
Promising Prostate Cancer Pipeline Therapies in the various stages of development include Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.
December 2023: Amunix, a Sanofi Company announced a study of Phase 1 & 2 clinical trials for AMX-500 (SAR446329). The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expansion (Part 2).
November 2023: AstraZeneca announced a study of Phase 3 clinical trials for abiraterone acetate. The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
April 2023: Surface Oncology announced a study of phase 2 clinical trails for SRF617, etrumadenant, and zimberelimab. This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
August 2023: AstraZeneca announced a study of phase 3 clinical trials for olaparib and abiraterone acetate. The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

Request a sample and discover the recent advances in Prostate Cancer Treatment Drugs @ Prostate Cancer Infection Pipeline Outlook Report

In the Prostate Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Prostate Cancer Overview

The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate Cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S.

Find out more about Prostate Cancer Treatment Landscape @ Drugs for Prostate Cancer Treatment

Prostate Cancer Emerging Drugs Profile

Pembrolizumab: Merck & Co
Talazoparib: Pfizer
ODM-208: Orion
ZEN 3694: Zenith Epigenetics
EPI-7386: ESSA Pharma

Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the Prostate Cancer therapies. The Prostate Cancer companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

DelveInsight’s Prostate Cancer pipeline report covers around 200+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Prostate Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Learn more about the emerging Prostate Cancer Pipeline Therapies @ Prostate Cancer Clinical Trials Assessment

Scope of the Prostate Cancer Pipeline Report

Coverage- Global
Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
Prostate Cancer Pipeline Therapies- Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.

Dive deep into rich insights for new drugs for Prostate Cancer treatment, Visit @ Prostate Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Prostate Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Pembrolizumab: Merck & Co
Drug profiles in the detailed report….
Mid Stage Products (Phase II)
ODM-208: Orion Pharma
Drug profiles in the detailed report….
Early Stage Products (Phase I)
EPI 7386: ESSA Pharma
Drug profiles in the detailed report….
Preclinical and Discovery Products
Drug name: Company name
Drug profiles in the detailed report…
Inactive Products
Prostate Cancer Key Companies
Prostate Cancer Key Products
Prostate Cancer- Unmet Needs
Prostate Cancer- Market Drivers and Barriers
Prostate Cancer- Future Perspectives and Conclusion
Prostate Cancer Analyst Views
Prostate Cancer Key Companies
Appendix

For further information on the Prostate Cancer pipeline therapeutics, reach out to Prostate Cancer Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics

Rheumatoid Arthritis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences

DelveInsight’s, “Rheumatoid Arthritis Pipeline Insight 2023” report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in the Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Rheumatoid Arthritis Pipeline Report

DelveInsight’s Rheumatoid Arthritis pipeline report depicts a robust space with 95+ active players working to develop 100+ pipeline therapies for Rheumatoid Arthritis treatment.
The leading companies working in the Rheumatoid Arthritis Market include Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc. PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences Inc., ICMBIO, and others.
Promising Rheumatoid Arthritis Pipeline Therapies in the various stages of development etanercept, M2951, Adalimumab, methotrexate, ENBREL®, Enbrel, Certolizumab pegol, LY3871801, and others.
November 2023: SynAct Pharma Aps announced a study of Phase 2 clinical trials for 100 mg AP1189. The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate (MTX).
October 2023: Eli Lilly and Company announced a study of Phase 2 clinical trials for LY3871801. The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
August 2023: Eli Lilly and Company announced a study of phase 4 clinical trials for Baricitinib and TNF Inhibitor. This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors concerning venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
August 2023: Teijin America Inc. announced a study of phase 1 clinical trials for TCK-276. The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).

Request a sample and discover the recent advances in Rheumatoid Arthritis Treatment Drugs @ Rheumatoid Arthritis Pipeline Outlook Report

In the Rheumatoid Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease known to adversely impact the joints of the body. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body; on the onset of disease, the immune response primarily attacks and harms the joints.

Find out more about Rheumatoid Arthritis Treatment Landscape @ Drugs for Rheumatoid Arthritis Treatment

Rheumatoid Arthritis Emerging Drugs Profile

SM03: SinoMab
SHR0302: Jiangsu Hengrui Medicine
RC18: RemeGen
Zalunfiban: CeleCor Therapeutics
ABBV-3373: Abbvie
Dazodalibep: Horizon Therapeutics
AP1189: Synact Pharma
Dekavil: Philogen

Rheumatoid Arthritis Pipeline Therapeutics Assessment

There are approx. 95+ key companies which are developing the Rheumatoid Arthritis therapies. The Rheumatoid Arthritis companies which have their Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. Phase I/II include, RHEACELL.

DelveInsight’s Rheumatoid Arthritis pipeline report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Rheumatoid Arthritis Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Learn more about the emerging Rheumatoid Arthritis Pipeline Therapies @ Rheumatoid Arthritis Clinical Trials Assessment

Scope of the Rheumatoid Arthritis Pipeline Report

Coverage- Global
Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Rheumatoid Arthritis Companies- Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc. PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences Inc., ICMBIO, and others.
Rheumatoid Arthritis Pipeline Therapies- etanercept, M2951, Adalimumab, methotrexate, ENBREL®, Enbrel, Certolizumab pegol, LY3871801, and others.

Dive deep into rich insights for new drugs for Rheumatoid Arthritis treatment, Visit @ Rheumatoid Arthritis Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Rheumatoid Arthritis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Rheumatoid Arthritis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
SM03: SinoMab
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABBV-3373: Abbvie
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SVT 6A4710: Servatus Biopharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SYN060: Synermore Biologics Co., Ltd.
Drug profiles in the detailed report…..
Preclinical Stage Products
CABA-201: Cabaletta Bio
Drug profiles in the detailed report…..
Inactive Products
Rheumatoid Arthritis Collaborations Assessment- Licensing / Partnering / Funding
Rheumatoid Arthritis Unmet Needs
Rheumatoid Arthritis Market Drivers and Barriers
Appendix

For further information on the Rheumatoid Arthritis pipeline therapeutics, reach out to Rheumatoid Arthritis Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences

Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others

DelveInsight’s, “Exosomes Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 110+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Exosomes Pipeline Report

DelveInsight’s Exosomes pipeline report depicts a robust space with 60+ active players working to develop 110+ pipeline therapies for Exosomes treatment.
The leading companies working in the Exosomes Market include Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
Promising Exosomes Pipeline Therapies in the various stages of development include Exosome ointment, EV-Pure™, Zofin, Olmutinib, and others.
December 2023: Direct Biologics LLC announced a study of Phase 3 clinical trials for ExoFlo. To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
November 2023: Organicell Regenerative Medicine announced a study of Phase 1 & 2 clinical trials for Zofin. The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
October 2023: Vitti Labs LLC announced a study of Phase 1 clinical trials for EV-Pure™. The VL-POI-01 study is designed to evaluate the safety and efficacy of human placental mesenchymal stem cell derived exosome treatment in patients with premature ovarian insufficiency (POI) and diminished ovarian reserve.

Request a sample and discover the recent advances in Exosomes Treatment Drugs @ Exosomes Pipeline Outlook Report

In the Exosomes pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Exosomes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Exosomes Overview

An exosome is a type of extracellular vesicle (EV), a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages released by most cells. Exosomes are released from cells upon fusion of an intermediate endocytic compartment, the multivesicular body (MVB), with the plasma membrane. This liberates intraluminal vesicles (ILVs) into the extracellular milieu and the vesicles thereby released are what we know as exosomes.

Find out more about Exosomes Treatment Landscape @ Drugs for Exosomes Treatment

Exosomes Emerging Drugs Profile

CAP-1002: Capricor
Progenza: Regeneus
AGLE 102: Aegle Therapeutics
Zofin: Organicell Regenerative Medicine
Exo-101: Exogenus Therapeutics
COYA 201: Coya Therapeutics

Exosomes Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for Exosomes. The Exosomes Companies which have their Exosomes drug candidates in the most advanced stage, i.e. phase III include, Capricor.

DelveInsight’s Exosomes pipeline report covers around 110+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Exosomes Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Learn more about the emerging Exosomes Pipeline Therapies @ Exosomes Clinical Trials Assessment

Scope of the Exosomes Pipeline Report

Coverage- Global
Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Exosomes Companies- Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
Exosomes Pipeline Therapies- Exosome ointment, EV-Pure™, Zofin, Olmutinib, and others.

Dive deep into rich insights for new drugs for Exosomes Treatment, Visit @ Exosomes Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Exosomes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Exosomes– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
CAP-1002: Capricor
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Progenza: Regeneus
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
StemXO Endosome Therapy: Stem XO Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Exo-101: Exogenus Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Exosome – Collaborations Assessment- Licensing / Partnering / Funding
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Appendix

For further information on the Exosomes pipeline therapeutics, reach out @ Exosomes Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others

Obesity Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, and others.

DelveInsight’s, “Obesity Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.

Key Takeaways from the Obesity Pipeline Report

DelveInsight’s Obesity pipeline report depicts a robust space with 100+ active players working to develop 130+ pipeline therapies for Obesity treatment.
The leading companies working in the Obesity Market include 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others.
Promising Obesity Pipeline Therapies in the various stages of development include Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others.
December 2023: Rhythm Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Setmelanotide. The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 60 weeks.
December 2023: Pfizer announced a study of Phase 1 clinical trials for Rosuvastatin and Midazolam. A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity.

Request a sample and discover the recent advances in Obesity Treatment Drugs @ Obesity Pipeline Report

In the Obesity pipeline report, detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Obesity Overview

Obesity is recognized as a chronic or non-communicable disease, a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity or body fatness which can manifest metabolically and not just concerning the size of the body.

Find out more about Obesity Treatment Landscape @ Drugs for Obesity Treatment

Obesity Emerging Drugs Profile

Semaglutide oral: Novo Nordisk
Tirzepatide: Eli Lilly and Company
Tesomet: Saniona
RZL-012: Raziel Therapeutics
CT-868: Carmot Therapeutics
EMP16: Empros Pharma
DD01: D&D Pharmatech
ZP 8396: Zealand Pharma
ERX-1000: ERX Pharmaceuticals

Obesity Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Obesity. The Obesity companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.

DelveInsight’s Obesity pipeline report covers around 130+ Obesity products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Obesity Pipeline Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Learn more about the emerging Obesity Pipeline Therapies @ Obesity Clinical Trials Assessment

Scope of the Obesity Pipeline Report

Coverage- Global
Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Obesity Companies- 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others.
Obesity Pipeline Therapies- Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others.

Dive deep into rich insights for new drugs for Obesity treatment, Visit @ Obesity Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Obesity Overview
Obesity Pipeline Therapeutics
Obesity Therapeutic Assessment
Late Stage Products (Phase III)
Oral Semaglutide: Novo Nordisk
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
RZL-012: Raziel Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DD01: D&D Pharmatech
Drug profiles in the detailed report…..
Inactive Obesity Products
Obesity Key Companies
Obesity Key Products
Obesity Unmet Needs
Obesity Market Drivers
Obesity Market Barriers
Obesity Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
Appendix

For further information on the Obesity pipeline therapeutics, reach out @ Obesity Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, and others.

Metastatic Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in the Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 130+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.
The leading companies working in the Metastatic Colorectal Cancer Market include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.
September 2023: Bristol-Myers Squibb announced a study of phase 3 clinical trials for Ipilimumab, Oxaliplatin, and Leucovorin. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
October 2023: Arcus Biosciences Inc. announced a study of Phase 1 & 2 clinical trials for AB680, Etrumadenant, Zimberelimab, and Bevacizumab. This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

Request a sample and discover the recent advances in Metastatic Colorectal Cancer Treatment Drugs @ Metastatic Colorectal Cancer Pipeline Report

In the Metastatic Colorectal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Metastatic Colorectal Cancer Overview

Cancer cells may break away from a tumor in the colon or rectum and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ. Even though the cancer has spread to a new organ, it is still named after the part of the body where it originally started.

Find out more about Metastatic Colorectal Cancer Therapeutics Assessment @ Metastatic Colorectal Cancer Preclinical and Discovery Stage Products

Metastatic Colorectal Cancer Emerging Drugs Profile

Adagrasib (MRTX849): Mirati Therapeutics
QL-1203: Qilu Pharmaceutical
ZN-c3: Zentalis Pharmaceuticals

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the Metastatic Colorectal Cancer pipeline therapies. The Metastatic Colorectal Cancer companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

Learn more about the emerging Metastatic Colorectal Cancer Pipeline Therapies @ Metastatic Colorectal Cancer Clinical Trials Assessment

Scope of the Metastatic Colorectal Cancer Pipeline Report

Coverage- Global
Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.

Dive deep into rich insights for new drugs for Metastatic Colorectal Cancer Treatment, Visit @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Metastatic colorectal cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Metastatic colorectal cancer Collaboration Deals
Late Stage Products (Phase III)
MRTX849: Mirati Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AK-112: Akeso Biopharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SY 5609: Syros Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Metastatic colorectal cancer Key Companies
Metastatic colorectal cancer Key Products
Metastatic colorectal cancer- Unmet Needs
Metastatic colorectal cancer- Market Drivers and Barriers
Metastatic colorectal cancer- Future Perspectives and Conclusion
Metastatic colorectal cancer Analyst Views
Metastatic colorectal cancer Key Companies
Appendix

For further information on the Metastatic Colorectal Cancer Pipeline therapeutics, reach out to Metastatic Colorectal Cancer Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd

Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 |Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, and others.

DelveInsight’s, “Diabetes Pipeline Insights 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Diabetes Pipeline Report

DelveInsight’s Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
The leading companies working in the Diabetes Market include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
Promising Diabetes Pipeline Therapies in the various stages of development include LY2963016, Lantus, OAMs, ORMD-0801, Exenatide, Cotadutide, Saxagliptin, Muraglitazar, Pioglitazone, and others.
November 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Ertugliflozin 5 mg and Metformin. This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
September 2023: Adocia announced a study of Phase 1 clinical trials for Euglycemic clamp with BC Combo THDB0207. This is a randomised, double-blind, four-period crossover euglycaemic clamp trial in subjects with type 2 diabetes. Each subject will be randomly allocated to one of four treatment sequences. Each sequence will comprise 3 different single doses of BC Combo THDB0207 (Low dose, Medium dose, and High dose) and one single dose of Humalog® Mix25.

Request a sample and discover the recent advances in Diabetes Treatment Drugs @ Diabetes Pipeline Outlook Report

The Diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Diabetes drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Diabetes clinical trial landscape.

Diabetes Overview

Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas.

Find out more about Diabetes Treatment Landscape @ Drugs for Diabetes Treatment

Diabetes Emerging Drugs Profile

Enavogliflozin – Daewoong
Golimumab – Janssen Biotech

Diabetes Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the therapies for Diabetes. The Diabetes companies which have their Diabetes drug candidates in the most advanced stage, i.e. phase III include, Daewoong.

DelveInsight’s Diabetes Pipeline Report covers around 200+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
intravitreal
Subretinal
Topical.
Molecule Type

Diabetes Pipeline Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Learn more about the emerging Diabetes Pipeline Therapies @ Diabetes Clinical Trials Assessment

Scope of the Diabetes Pipeline Report

Coverage- Global
Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Diabetes Companies- Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
Diabetes Pipeline Therapies- LY2963016, Lantus, OAMs, ORMD-0801, Exenatide, Cotadutide, Saxagliptin, Muraglitazar, Pioglitazone, and others.

Dive deep into rich insights for new drugs for Diabetes treatment, Visit @ Diabetes Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Diabetes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diabetes – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetes Collaboration Deals
Late Stage Products (Phase III)
Enavogliflozin: Daewoong
Mid Stage Products (Phase II)
Golimumab: Janssen Biotech
Early Stage Products (Phase II/I)
IMCY-0098: ImCyse
Pre-clinical and Discovery Stage Products
ENT-001: Enthera
Drug profiles in the detailed report…..
Inactive Products
Diabetes Key Companies
Diabetes Key Products
Diabetes- Unmet Needs
Diabetes- Market Drivers and Barriers
Diabetes- Future Perspectives and Conclusion
Diabetes Analyst Views
Diabetes Key Companies
Appendix

For further information on the Diabetes pipeline therapeutics, reach out @ Diabetes Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 |Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, and others.

Type 2 Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, and others.

DelveInsight’s, “Type 2 Diabetes Mellitus Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 2 Diabetes mellitus pipeline landscape. It covers the Type 2 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 2 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Type 2 Diabetes Pipeline Report

DelveInsight’s Type 2 Diabetes pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Type 2 Diabetes treatment.
The leading companies working in the Type 2 Diabetes Market include Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, KeyBioscience AG, Adocia, Jiangsu Hengrui Medicine, Bristol myers Suibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals, Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie, and others.
Promising Type 2 Diabetes Pipeline Therapies in the various stages of development include Muraglitazar, Pioglitazone, Cotadutide, ORMD-0801 (qd), glargine, detemir, saxagliptin, sitagliptin, and others.
November 2023: Prokidney announced a study of Phase 3 clinical trials for Renal Autologous Cell Therapy (REACT). The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
November 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Ertugliflozin 5 mg and Metformin. This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.

Request a sample and discover the recent advances in Type 2 Diabetes Treatment Drugs @ Type 2 Diabetes Pipeline Outlook Report

The Type 2 Diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Type 2 Diabetes drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Type 2 Diabetes clinical trial landscape.

Type 2 Diabetes Overview

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Diabetes mellitus are of three types Type1, Type 2 and Gestational Diabetes.

Find out more about Type 2 Diabetes Treatment Landscape @ Drugs for Type 2 Diabetes Treatment

Type 2 Diabetes Emerging Drugs Profile

Sotagliflozin: Lexicon Pharmaceuticals
ORMD0801: Oramed Pharmaceuticals
LY3209590-Eli lily and Company
HM12460A: Hanmi Pharmaceuticals
HM14220:Hanmi Pharmaceuticals

Type 2 Diabetes Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Postoperative Pain. The Type 2 Diabetes companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Lexicon Pharmaceuticals.

DelveInsight’s Type 2 Diabetes pipeline report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Type 2 Diabetes mellitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type

Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule
Product Type

Learn more about the emerging Type 2 Diabetes Pipeline Therapies @ Type 2 Diabetes Clinical Trials Assessment

Scope of the Type 2 Diabetes Pipeline Report

Coverage- Global
Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Type 2 Diabetes Companies- Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, KeyBioscience AG, Adocia, Jiangsu Hengrui Medicine, Bristol myers Suibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals, Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie, and others.
Type 2 Diabetes Pipeline Therapies- Muraglitazar, Pioglitazone, Cotadutide, ORMD-0801 (qd), glargine, detemir, saxagliptin, sitagliptin, and others.

Dive deep into rich insights for new drugs for Type 2 Diabetes treatment, Visit @ Type 2 Diabetes Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Type 2 Diabetes mellitus: Overview
Pipeline Therapeutics
Therapeutic Assessment
Type 2 Diabetes mellitus – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Sotagliflozin: Lexicon Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
LY3209590: Eli lily and Company
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
HM12460A: Hanmi Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
HM14220: Hanmi Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Type 2 Diabetes mellitus- Key Companies
Type 2 Diabetes mellitus- Key Products
Type 2 Diabetes mellitus – Unmet Needs
Type 2 Diabetes mellitus – Market Drivers and Barriers
Type 2 Diabetes mellitus – Future Perspectives and Conclusion
Type 2 Diabetes mellitus Analyst Views
Type 2 Diabetes mellitus Key Companies
Appendix

For further information on the Type 2 Diabetes pipeline therapeutics, reach out @ Type 2 Diabetes Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 2 Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, and others.

Steel Wire Rope & Plastic Rope Market to a Projected Valuation of $17.5 Billion by 2026| MarketsandMarkets™

“Browse 270 market data Tables and 58 Figures spread through 257 Pages and in-depth TOC on “Steel Wire Rope & Plastic Rope Market””

Steel Wire Rope & Plastic Rope Market by Type of Lay (Regular Lay, Lang Lay), Material Type (PP, PET, Nylon, HMPE, Specialty fibers), Application (Marine & Fishing, Sports & Leisure, Oil & Gas, Industrial & Crane) Region – Global Forecast to 2026

The global steel wire rope & plastic rope market size was USD 11.9 billion in 2021 and is expected to reach USD 17.5 billion by 2026, projecting a CAGR of 8.0% between 2021 and 2026. Steel wire ropes & plastic ropes are increasingly used in the marine & fishing, sports & leisure, oil & gas, industrial & crane, mining, construction, and other end-use applications. However, the outbreak of COVID-19 has created ripples across various application industries leading to reduced demand for steel wire ropes & plastic ropes. Due to the lockdown scenario in Europe and North America, the demand for steel wire ropes & plastic ropes from oil & gas, industrial & crane, mining, construction, and other applications have declined sharply in 2020.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162936381

Steel wire ropes and plastic ropes have high applicability in the marine & fishing and mining sectors. Plastic ropes are less prone to corrosion and have floating properties that make them suitable for use in fishing activities. In mining applications, steel wire ropes are preferred due to their high load-bearing strength. In APAC, the fishing and mining sectors are among the booming sectors, especially in countries such as China, Indonesia, Japan, and India. APAC led the total aquaculture production and accounted for 89% of the global aquaculture production in 2013. In addition, APAC has the world’s largest mineral reserves. This is expected to help the steel wire ropes and plastic ropes manufacturers with immense growth opportunities in the region.

Steel wire ropes and plastic ropes have a higher strength-to-weight ratio, which is an important factor for various applications specially in the marine and fishing sector. Plastic ropes are used for various lifting and towing purposes in the marine industry. The property of plastic ropes to float in water makes them appropriate for use in this industry. Plastic ropes are used by tankers and cargo vessels, cruise ships and ferries, tug and salvage operators, offshore oil & gas contractors, naval ships, and port authorities for mooring, towing, and safety lines.

Over the past years, steel wire ropes & plastic ropes manufacturers have strengthened their position in the global steel wire rope & plastic rope market by adopting expansions, partnerships, agreements, new product/technology launches, joint ventures, contracts, and mergers & acquisitions. However, owing to lockdown announced by several countries in 2020, the demand for steel wire ropes & plastic ropes from oil & gas, mining, construction, and other end-use applications has declined sharply, which resulted in declined demand for steel wire ropes & plastic ropes.

The major manufacturers profiled in this report include Cortland Limited (US), WireCo WorldGroup Inc., (US), Samson Rope Technologies (US), Southern Ropes (South Africa) and English Braids Ltd. (UK), are some of the key players in the steel wire rope & plastic rope market. Marlow Ropes (UK), Teufelberger Holding AG (Austria), Bekaert SA (Belgium), Usha Martin (India), Gustav Wolf (Germany), and among others.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=162936381

Cortland Limited (US) works through its subsidiaries: Cortland Cable (US), Cortland Puget Sound Rope (US), Cortland Fibron BX (UK), and Cortland Selantic (Norway). Cortland Limited operates as a subsidiary of Actuant Corporation (US), a diversified industrial company with operations in more than 30 countries worldwide. The company provides custom solutions and offers its products to various industries such as oil & gas, marine, aerospace & defense, and medical. Its product line is categorized into synthetic rope & strength members, lifting slings & tethers, umbilical, electro-optical-mechanical cables, and medical textile & strength members.

WireCo WorldGroup Inc., (US) is one of the leading manufacturers of steel wire & synthetic ropes, fabricated products, specialty steel wires, synthetic yarns, and electromechanical cables. It has three business segments—ropes, specialty wires, and engineered products. The company markets its products under multiple brands: Union, MacWhyte, Casar, Camesa, Oliveira, Wireline Works, Phillystran, Lankhorst Ropes and Yarns, Drumet, and US Reel.

The steel wire rope & plastic rope business of these companies is severely affected due to the outbreak of COVID – 19 pandemic. Reduced demand for steel wire ropes & plastic ropes from several applications and disruption in the supply chain have compelled the steel wire ropes & plastic ropes manufacturing companies to operate at partial capacities. However, several steel wire rope & plastic rope manufacturers have focused their concentration on new product development. These developments, coupled with end-use applications resuming their operations at full capacities, would create demand for steel wire ropes & plastic ropes during the forecast period.

Read Our Trending Press Release Below:

Liquid Adhesives Market– Global Forecast to 2025

Glass Fiber Yarn Market– Global Forecast to 2027

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/steel-wire-plastic-rope-market-162936381.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Steel Wire Rope & Plastic Rope Market to a Projected Valuation of $17.5 Billion by 2026| MarketsandMarkets™